Interview With Richard Skaife

Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study’s primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.

And again, every secondary research objective heavily FAVORED psilocybin.

This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)

Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​

General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​​ ​#psilocybin​​​​ #shroomboom

Hey psychedelic investors, this week we have Big Updates on MindMed, Compass, NUMI TRYP, TRUFF, ATAI, SHRM and LOBE Sciences and some amazing Ayahuasca study results which are detrimental to DMT research and this molecule potential effects on depression and anxiety.

Timestamps:
0:00 – Intro
0:52- Effects of DMT, taken using the ayahuasca drink, on depression and anxiety
5:26 – MindMed ( MMED / MNMD / MMQ ) stared trading on NASDAQ
6:01 – MindMed finishes phase2a trials for Project LUCY
8:15 – Atai Life Sciences To IPO soon on the Nasdaq and plans to raise $100 million
9:17 – Compass Pathways ( CMPS) to raise $144 million dollars
10:35 – Numinus Wellness ( NUMI ) to begin phase 1 trial for naturally extracted psilocybin in their lab
12:15 TRYP Therapeutics (TRYP) to begin 2 phase 2a trials in 2021
13:50 – Champignon Brands (SHRM) to restart trading in Canada
14:31 – Lobe Sciences (LOBE) & Core one Labs ( CLABF) to create a Joint Venture
15:34 – Red Light Holland (TRUFF) has increased its points of sale by 144% and TRUFF and Halo Collective create Red Light Oregn, INC

Link to Numinus (NUMI) press release: https://www.newswire.ca/news-releases/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab-879795202.html?fbclid=IwAR1SmpbsTmXLs-mEy3vsUtAGKKk_xpf3FxJB3n2C-55zGJjiF0naXRetoUs

Link to Compass Pathways (CMPS) : https://www.globenewswire.com/news-release/2021/04/27/2218191/0/en/COMPASS-Pathways-launches-proposed-public-offering.html https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30

Link To Atai life Sciences: https://www.atai.life/

Link To MindMed (MMED / MNMD / MMQ) https://mindmed.co/
Link to MindMed clinical trial: https://clinicaltrials.gov/ct2/show/NCT03153579?term=lsd+anxiety&draw=2&rank=1

Link to Red LIght Holland (TRUFF) : https://www.newsfilecorp.com/release/81879/Red-Light-Holland-and-Halo-Collective-Create-Red-Light-Oregon-Inc.-Forwarding-Intentions-to-Enter-Oregon-Medicinal-Psychedelic-Market
https://www.cnbc.com/2021/04/21/atai-ipo-peter-thiel-backed-psychedelics-firm-to-raise-100-million.html

Link to Champignon Brands (SHRM) : https://www.prnewswire.com/news-releases/champignon-brands-announces-revocation-of-cease-trade-orders-301275526.html

Link to DMT study: https://www.sciencedirect.com/science/article/pii/S2666915321000251?fbclid=IwAR1-0HC9fxkL2Z47TEubMGsrqKInj61xLvBK4OW_C3FEQgv5VomoCSoNeQo

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #numiStock

Top 10 Psychedelic stocks to own according to PSIL ETF (DO I AGREE?)

What’s up Psychedelic Investors!?! Today we are looking at the actively managed Psychedelic Medicines ETF, PSIL, run by Advisor Shares.

Before we get into that though, make sure you go check out psychedelicspotlight.com and sign up for their weekly newsletter. I am featured in each one, with a 3:30 clip summarizing the biggest events in the psychedelic medicines world over the past week. It is essential!

On today’s episode we go through each of the top ten holding in PSIL, including MindMed (MNMD /MMED), Compass Pathways (CMPS), atai Life Sciences (atai), Cybin (CYBN), Field Trip (FTRP), Numinus, (NUMI) and more.

For some of the lesser known companies, such as Seelos Therapeutics, Wesana Health and GreenBrook TMS, we give a brief rundown of the company.

Investing in an actively managed psychedelic stocks ETF can be a great opportunity for those who believe in the ability of psychedelics to heal mental health issues such as PTSD and depression, but are not sure which companies are best to invest in. PSIL is actively managed, which means that their team of experts are picking what they believe to be the best stocks in the industry.

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PSIL #ThePsychedelicInvestor

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
2. Study looking at the creativity benefits of taking psilocybin
3. Compass Pathways (CMPS) has amazing new price targets
4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
5. A couple of updates on decriminalization efforts

Timestapms:

0:00 – Intro
1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.

I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks ​#Numi #Mindmed